ABEOABEONA THERAPEUTICS INC.

Nasdaq abeonatherapeutics.com


$ 4.42 $ -0.20 (-4.35 %)    

Friday, 17-May-2024 15:59:57 EDT
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 4.4
$ 4.58
$ 4.40 x 200
$ 4.42 x 200
$ 4.41 - $ 4.61
$ 2.83 - $ 9.01
523,022
na
75.57M
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-18-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 07-28-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-24-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-09-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 03-18-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-16-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-15-2017 03-31-2017 10-Q
30 03-30-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-15-2016 06-30-2016 10-Q
33 05-16-2016 03-31-2016 10-Q
34 03-30-2016 12-31-2015 10-K
35 11-16-2015 09-30-2015 10-Q
36 08-14-2015 06-30-2015 10-Q
37 05-14-2015 03-31-2015 10-Q
38 03-31-2015 12-31-2014 10-K
39 11-14-2014 09-30-2014 10-Q
40 08-14-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-maintains-overweight-on-abeona-therapeutics-lowers-price-target-to-21

Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and lowers the price ...

 fda-rejects-approval-of-abeona-therapeutics-skin-disorder-treatment-shares-sink

Abeona Therapeutics' pz-cel gets the FDA's Complete Response Letter and Abeona's plans for fulfilling Chemistry Man...

 cantor-fitzgerald-reiterates-overweight-on-abeona-therapeutics-maintains-36-price-target

Cantor Fitzgerald analyst Kristen Kluska reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and maintains $36 pr...

Core News & Articles
Market-Moving News for April 23rd
04/23/2024 12:35:52

ABEO: -55% | Abeona Therapeutics shares are trading lower after the company announced the FDA issued a Complete Response Letter...

 abeona-therapeutics-provides-regulatory-update-on-pz-cel-crl-did-not-identify-deficiencies-related-to-clinical-efficacy-or-clinical-safety-data-in-bla-and-no-new-clinical-studies-requested-by-fda-to-support-approval

Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies rela...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION